1021935-30-7Relevant academic research and scientific papers
ANTIDIABETIC BICYCLIC COMPOUNDS
-
Page/Page column 21-22, (2008/12/05)
Biaryl ethers in which one of the aromatic πngs is fused to a cycloalkyl or heterocyclic πng, which is attached to a thiazohdinedione or oxazohdmedione πng, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes melhtus, and of conditions that often occur with type 2 diabetes, including insulin resistance, obesity, and lipid disorders.
ANTIDIABETIC BICYCLIC COMPOUNDS
-
Page/Page column 20, (2008/12/05)
Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.
ANTIDIABETIC BICYCLIC COMPOUNDS
-
Page/Page column 38-39, (2008/06/13)
Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
